John LaMattina, Contributor

Author's details

Name: John LaMattina, Contributor
Date registered: October 19, 2016
URL: http://www.forbes.com/healthcare/

Latest posts

  1. Pharma Failures Actually Advance Medicine — October 16, 2018
  2. Biopharma Attacked For Excessive Profits On Drugs For Children — October 2, 2018
  3. Chinese Drug Maker Clarifies Development Strategy For Bringing Cancer Drug To The U.S. Market — September 26, 2018
  4. Chinese Drug Maker Clarifies Development Strategy For Bringing Cancer Drug To The U.S. Market — September 26, 2018
  5. Chinese Drug Maker Clarifies Development Strategy For Bringing Cancer Drug To The U.S. Market — September 26, 2018

Author's posts listings

Pharma Failures Actually Advance Medicine

The fact is we want big pharma to work on these difficult challenges. No other entity can do this.

Biopharma Attacked For Excessive Profits On Drugs For Children

These laws have transformed the way medicines are developed for pediatric populations.

Chinese Drug Maker Clarifies Development Strategy For Bringing Cancer Drug To The U.S. Market

Given these plans, Chi-Med is open to U.S. partnerships for development of cancer therapies that incorporate fruquintinib.

Chinese Drug Maker Clarifies Development Strategy For Bringing Cancer Drug To The U.S. Market

Given these plans, Chi-Med is open to U.S. partnerships for development of cancer therapies that incorporate fruquintinib.

Chinese Drug Maker Clarifies Development Strategy For Bringing Cancer Drug To The U.S. Market

Given these plans, Chi-Med is open to U.S. partnerships for development of cancer therapies that incorporate fruquintinib.

Harvard Professor’s Attack On Pharma’s Clinical Trials Is Absurd

Yes, we must be vigilant to be certain that studies are run ethically and that results are published accurately and on time. But, to say that academic-industry relationships are full of “corruption” is both wrong and irresponsible.

Can A Cancer Drug Originated In China Be A Success In The U.S.?

Fruquintinib may not be the best test case for bringing a homegrown China medicine to the U.S.

An Unwarranted Attack On Rare Disease Research

Hearing a parent agonize over the plight of their child who suffers from a rare disease is heart wrenching. For these families, research into rare disease drugs hasn’t come close to “reaching an extreme”.

Why Aren’t Prison Inmates With Hepatitis C Being Treated?

As a matter of general health policy, states should aggressively treat hepatitis C in prisons.

The Biopharmaceutical Industry Provides 75% Of The FDA’s Drug Review Budget. Is This A Problem?

If you were to ask the CEOs of Pfizer, Merck, Lilly, etc., they would be more than happy to drop the “user fees” and have Congress fully fund the FDA via other funding mechanisms.

Older posts «

Explore the Archive